Tackling Prostate Cancer with Theranostic E5B9-Bombesin Target Modules (TMs): From Imaging to Treatment with UniCAR T-Cells
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26062686 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Liliana R Loureiro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Bombesin, T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dianne and Irving Kipnes Foundation.
Abstract (Originalsprache)
Target modules (TMs), intermediate molecules required for UniCAR T-cell therapy, are promising molecules for immunotheranostic approaches. In the current work, we developed TMs containing a monomeric or dimeric form of the antagonist bombesin peptide (BBN2) and assessed their potential for diagnostic imaging using positron emission tomography (PET) as well as immunotherapy in combination with UniCAR T-cells to target and image GRPR expression in prostate cancer. Synthesized monomeric and dimeric BBN2 TMs retained binding to GRPR in vitro. Both BBN2 TMs specifically activated and redirected UniCAR T-cells to eradicate PC3 and LNCaP cancer cells with high efficiency and in a comparable manner. UniCAR T-cells retained a non-exhausted memory phenotype favorable to their persistence and fitness. The 68Ga-labeled BBN2 TMs showed proof-of-target towards GRPR in PC3 and LNCaP xenografts with similar uptake profiles for both BBN2 TMs in dynamic PET experiments. Clearance occurred exclusively through renal elimination. A tremendously increased in vivo metabolic stability of the BBN2 TMs was observed compared to their counterparts without E5B9. Both monomeric and dimeric BBN2 TMs represent novel and promising immunotheranostic tools for application in prostate cancer with exceptionally high in vivo metabolic stability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany.
- Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada.
- Cancer Research Institute of Northern Alberta (CRINA), University of Alberta, Edmonton, AB T6G 2E1, Canada.
- Department of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary.
- German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- National Center for Tumor Diseases Dresden (NCT/UCC), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
ORCID-Profile: Cody N Bergman, Michael Bachmann
Förderung
- Dianne and Irving Kipnes Foundation
Zitieren
APA
Loureiro, L. R., Pike, S., Wuest, M., Bergman, C. N., JØrgensen, K. R., Bergmann, R., Feldmann, A., Wuest, F., & Bachmann, M. (2025). Tackling Prostate Cancer with Theranostic E5B9-Bombesin Target Modules (TMs): From Imaging to Treatment with UniCAR T-Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062686
Vancouver
Loureiro LR, Pike S, Wuest M, Bergman CN, JØrgensen KR, Bergmann R, et al. Tackling Prostate Cancer with Theranostic E5B9-Bombesin Target Modules (TMs): From Imaging to Treatment with UniCAR T-Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062686
BibTeX
@article{Loureiro2025,
author = {Loureiro, Liliana R and Pike, Susan and Wuest, Melinda and Bergman, Cody N and JØrgensen, Kira R and Bergmann, Ralf and Feldmann, Anja and Wuest, Frank and Bachmann, Michael},
title = {Tackling Prostate Cancer with Theranostic E5B9-Bombesin Target Modules (TMs): From Imaging to Treatment with UniCAR T-Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26062686}
}
EUVIMED